陆小云｜暨南大学｜学者主页

2026

2025年美国FDA批准的小分子激酶抑制剂综述

郝增君，池玲玲，罗奕欣，陆小云

《药学进展》

2026

Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance.

Yi Chen, Qiupei Liu, Si-Jie Yang, Jian Ding, Xiaoyun Lu, Hua Xie

Acta Pharmacologica Sinica

DOI

2026

Discovery of Arginine-Reactive Covalent Kinase Inhibitors Overcoming Clinical Drug Resistance

Zuqin Wang, Xuan Wang, Hong Zhang, Jiahuan He, Lu Wang, Ling Li, Peng Chen, Jibo Kang, Xiaojuan Song, Zhengchao Tu, Zhang Zhang, Zhimin Zhang, Shao Qin Yao, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2026

Discovery and Synthesis of Selective Casein Kinase 1δ Degraders for Suppressing Oncogenic NRAS-Mutant Melanoma

Changfa Zhang, Yalei Wen, Jianqiao Yi, Xuan Wang, Junping Pei, Yalin Tu, Ren‐Wang Jiang, Tongzheng Liu, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2026

p38β-mediated BiP phosphorylation drives stemness and chemoresistance by suppressing UPR activation in hepatocellular carcinoma

Liang Xu, Ianto Bosheng Huang, Minghe Zhang, Yunong Xie, Bing Li, Linglin Liu, Long Hin Ng, Yimiao He, Yan Liu, Tin Lok Wong, Xiaoyun Lu, Terence K. Lee, Jing‐Ping Yun, Lei Jin, Stephanie Ma, Man Tong

Nature Communications

DOI

2026

Structure-Based Design of 4-(1-Methyl-1 H -indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors

Wenjian Zhu, Xiaojuan Chen, Xiaofei Li, Jieying Lin, Xiaojing Lin, Xueru Liu, Wuqing Deng, Xiaojuan Song, Zhengchao Tu, Adam Vorn Patterson, Jeff Bruce Smaill, Yongheng Chen, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2026

Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance

Shuang Xiang, Xiaojuan Chen, Jieying Lin, Xiaojing Lin, Qianmeng Lin, Xiaojuan Song, Ling Yan, Haoran Peng, Zhengchao Tu, Adam Vorn Patterson, Jeff Bruce Smaill, Yalin Tu, Yongheng Chen, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2026

Covalent Recruitment of E3 Ligases: A New Path for Rational Design of Protein Degraders

Ziyan Yu, Jianqiang Zhang, Man Tong, Lanlan Zang, Jie Sun, Xiaoyun Lu

Medicinal Research Reviews

DOI

2026

Design, Synthesis, and Antimicrobial Activity of Novel Cyt- bd Inhibitors Targeting Energy Compensation in Mycobacterium tuberculosis

Qiao Qin, Zhuoheng Liu, Chen‐Yi Cheung, Jinxu Xu, Sadaf Kalsum, Hang Yu, Maria Lerm, Hongri Gong, Matthew B. McNeil, Gregory Murray Cook, Susanna Brighenti, Yang Zhou, Xiaoyun Lu

ACS Medicinal Chemistry Letters

DOI

2026

Dual‐Site Covalent Targeting Enables BD2‐Selective BET Inhibition With Potent Antitumor Activity in Mice

Jibo Kang, Xuan Wang, Hong Zhang, Jieying Lin, Peng Chen, Zuqin Wang, Zengjun Hao, Fengfei Miao, Fengcai Zhang, Tao Li, Yusheng Xie, Junjian Wang, Zhimin Zhang, Shao Qin Yao, Xiaoyun Lu

Angewandte Chemie

DOI

2026

Generative Replica Exchange: A Flow-Based Framework for Accelerating Replica-Exchange Simulations

Shengjie Huang, Sijie Yang, Jianqiao Yi, Honghan Chen, Haoyang Guan, Rui Zheng, Haocong Liao, Muzammal Hussain, Yaoquan Tu, Xiaoyun Lu, Yang Zhou

Journal of Chemical Theory and Computation

DOI

2026

Large‐Scale Profiling of Kinase Degradation by Using Norbornene‐Based Hydrophobic Tag (HyT) Strategy

Mingxi Gu, Fengfei Miao, Lvyang Peng, Jie Sun, Peng Chen, Fang Yang, Jiachang Yan, Liqian Gao, Xiaoyun Lu, Shao Qin Yao, Peiyan Yuan

Angewandte Chemie

DOI

2026

List of contributors

Yi Chen, Yuanyuan Chen, Ke Ding, Yahui Ding, Wanjing Feng, Xueqin Hu, Jibo Kang, Chenzhong Liao, Huaxu Liu, Xiaoyun Lu, Yi Luo, Liang Ouyang, Junping Pei, Yu Rao, Wen Shuai, Chengliang Sun, Yalin Tu, Wang Danfeng, Guan Wang, Zi Wang, Chengwei Wu, Hua Xie, Zhouling Xie, Panpan Yang, Peng Yang, Jianqiao Yi, Kai Yuan, Chao Zhang, Jian Zhang, Quan Zhang, Kaijie Zhou, Yang Zhou, Ruidi Zhu, Wenjian Zhu

Elsevier eBooks

DOI

2026

Recent advances in HER2-targeted inhibitors for cancer therapy

Wenjian Zhu, Xiaoyun Lu

Pharmaceutical Science Advances

DOI

2026

Discovery of 4-((2S,5R)-2-((difluoromethoxy)methyl)-5-(4-(trifluoromethyl)phenyl)piperidin-1-yl)-N-((R)-1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)benzamide as a potent, orally available RORγt inverse agonist

Wei Cao, Bing Liu, Ning Kang, Shun Bai, Feng Wang, Lixuan Xue, Minxiong Li, Cliff C. Cheng, Fang Yang, Yingjun Zhang, Xiaoyun Lu

Bioorganic Chemistry

DOI

2026

Structure-Based Virtual Screening Discovers Potent PLK1 Inhibitors with Anticancer Activity

Qian Zhang, Wenxin Zhu, Yi Cai, Yao Meng, W.C. Tan, Jing Li, Xiaoyun Lu, Hongli Du

Journal of Chemical Information and Modeling

DOI

2025

Proteome-Wide Ligand and Target Discovery by Using Covalent Probes and Natural Products

J.R. Liu, Chaoming Huang, Shengrong Li, Lijie Peng, Yaoliang Sun, Jianzhang Yang, Shan Li, Shilin Xu, Xiaoyun Lu, Ke Ding, Zhengqiu Li

Journal of Medicinal Chemistry

DOI

2025

Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1 H -indole-3-yl)-5 H -pyrrolo[2,3- b ]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance

Wuqing Deng, Xiaojuan Chen, Ling Yan, Shuang Xiang, Xiaojuan Song, Lin Zhang, Xiaofei Li, Wenjian Zhu, Junping Pei, Xiaojing Lin, Adam Vorn Patterson, Jeff Bruce Smaill, Bingsheng Li, Zhengchao Tu, Yang Zhou, Yongheng Chen, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2025

Discovery of TBK1Molecular Glue Degraders as a Potential Strategy for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jing Guo, Haotian Tang, Wenchao Zhao, Yong Li, Shukai Song, Fang Feng, Shengjie Huang, Xuan Wang, Yang Zhou, Junping Pei, Dong Ming Guo, Hua Xie, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2025

Designing Macrocyclic Kinase Inhibitors Using Macrocycle Scaffold Hopping with Reinforced Learning (Macro-Hop)

Hong Liang, Shengjie Huang, Xinxin Xu, Zhao Yin, Muzammal Hussain, Xiaojuan Song, Jianqiao Yi, Yingqi He, Jing Guo, Zhengchao Tu, Zhang Zhang, Yang Zhou, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2025

WEE-family kinases in cancer: synthetic lethal interactions and drug discovery

Chaofan Wang, Xiaoyun Lu

Trends in Pharmacological Sciences

DOI

2025

Macrocycle-DB: a comprehensive database for macrocycle-based drug discovery

Minchuan Jiang, Tianyue Liu, Muzammal Hussain, Yi Luo, Rui Zheng, Tingjun Hou, Xiaoyun Lu, Yang Zhou

Nucleic Acids Research

DOI

2025

Cell‐Active, Irreversible Covalent Inhibitors Targeting a Surface‐Exposed Non‐Catalytic Lysine on Aurora a Kinase by Using Squarate Chemistry

Zuqin Wang, Xuan Wang, Yong Li, Peishan Li, Shengjie Huang, Peng Chen, Guanghui Tang, Xiaotong Ding, Zhang Zhang, Zhi‐Min Zhang, Yang Zhou, Shao Qin Yao, Xiaoyun Lu

Angewandte Chemie

DOI

2025

Comprehensive Drug-Likeness Prediction Using a Pretrained Transformer Model and Multitask Learning

Yi Cai, Qian Zhang, W.C. Tan, Jing Li, Xiao Dong Chen, Xiaoyun Lu, Hongli Du

Journal of Chemical Information and Modeling

DOI

2025

Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4

Jing Guo, Xiaojuan Chen, Xiaofei Li, Xuan Wang, Min Shao, Xiaojuan Song, Lin Zhang, Sheng-Jie Huang, Adam Vorn Patterson, Jeff Bruce Smaill, Yang Zhou, Xiangrong Yu, Yongheng Chen, Xiaoyun Lu

Bioorganic Chemistry

DOI

2025

Deciphering molecular specificity in MCL-1/BAK interaction and its implications for designing potent MCL-1 inhibitors

Hudie Wei, Haolan Wang, Shuang Xiang, Jiaqi Wang, Lingzhi Qu, Xiaojuan Chen, Ming Guo, Xiaoyun Lu, Yongheng Chen

Cell Death and Differentiation

DOI

2025

Cell‐Active, Arginine‐Targeting Irreversible Covalent Inhibitors for Non‐Kinases and Kinases

Peng Chen, Lu Wang, Xuan Wang, Jie Sun, Fengfei Miao, Zuqin Wang, Fang Yang, Menghua Xiang, Mingxi Gu, Shengrong Li, Jianzhong Zhang, Peiyan Yuan, Xiaoyun Lu, Zhi‐Min Zhang, Liqian Gao, Shao Qin Yao

Angewandte Chemie

DOI

2024

2022年FDA批准的激酶调节剂浅析

郑绚，陆小云

《药学学报》

2024

Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma

Yalei Wen, Hui Wang, Xiao Yang, Yingjie Zhu, Mei Li, Xiuqing Ma, Lei Huang, Rui Wan, Caishi Zhang, Shengrong Li, Hong-Ling Jia, Qin Guo, Xiaoyun Lu, Zhengqiu Li, Xiangchun Shen, Qiushi Zhang, Lu Si, Chengqian Yin, Tongzheng Liu

Nature Communications

DOI

2024

Design, Synthesis, and Biological Evaluation of Novel Diaminopyrimidine Macrocycles as Fourth Generation Reversible EGFR Inhibitors That Overcome Clinical Resistance to Osimertinib Mediated by C797S Mutation

Shiliang Hu, Linjiang Tong, Qiao Qin, Jiaxin Wen, Yan Li, Feng Fang, Kunzhong Wu, Yang Zhou, Jinsai Shang, Junjian Wang, Jinbao Liu, Hua Xie, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2024

Multidisciplinary Training for Fostering Next-Generation Medicinal Chemists

Bin Yu, Xiaoyun Lu, Junbiao Chang

Journal of Medicinal Chemistry

DOI

2024

NeoaPred: a deep-learning framework for predicting immunogenic neoantigen based on surface and structural features of peptide–human leukocyte antigen complexes

Dawei Jiang, Binbin Xi, W.C. Tan, Zixi Chen, Jinfen Wei, Meiling Hu, Xiaoyun Lu, Dong Chen, Hongmin Cai, Hongli Du

Bioinformatics

DOI

2024

Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1 -Amplified Breast Cancer

Chaofan Wang, Yan Fang, Ziqin Zhou, Zhuoheng Liu, Fang Fěng, Xuan Wan, Yan Li, Shuang Liu, Jian Ding, Zhimin Zhang, Hua Xie, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2024

Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies

Yang Zhou, Jibo Kang, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2024

Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors

Wuqing Deng, Xiaojuan Chen, Xiaojuan Chen, Hong Liang, Xiaojuan Song, Shuang Xiang, Jing Guo, Zhengchao Tu, Yang Zhou, Yongheng Chen, Xiaoyun Lu

European Journal of Medicinal Chemistry

DOI

2024

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity

Fang Yang, Qianmeng Lin, Xiaojuan Song, Huisi Huang, Xiaojuan Chen, Jianwen Tan, Yun Li, Yang Zhou, Zhengchao Tu, Hongli Du, Zhimin Zhang, Raquel Ortega, Xiaojing Lin, Adam Vorn Patterson, Jeff Bruce Smaill, Yongheng Chen, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2024

A patent review of small molecular inhibitors targeting EGFR exon 20 insertion (Ex20ins) (2019-present)

Wenjian Zhu, Junping Pei, Junping Pei, Xiaoyun Lu

Expert Opinion on Therapeutic Patents

DOI

2024

A Self-Assembled Nano-Molecular Glue (Nano-mGlu) Enables GSH/H 2 O 2 -Triggered Targeted Protein Degradation in Cancer Therapy

Jie Sun, Mingxi Gu, Liang Peng, Jing Guo, Peng Chen, Yalei Wen, Feng Fang, Xiaojuan Chen, Tongzheng Liu, Yongheng Chen, Xiaoyun Lu, Liqian Gao, Shao Qin Yao, Peiyan Yuan

Journal of the American Chemical Society

DOI

2024

Advances in Small-Molecule C-KIT/PDGFRα Inhibitors for the Treatment of Gastrointestinal Stromal Tumors

Xuan Zheng, Hong Liang, Yang Zhou, Xiaoyun Lu

Pharmaceutical Fronts

DOI

2024

Small Molecule-Induced Post-Translational Acetylation of Catalytic Lysine of Kinases in Mammalian Cells

Guanghui Tang, Xuan Wang, Huisi Huang, Manyi Xu, Xingyu Ma, Fengfei Miao, Xiaoyun Lu, Chong‐Jing Zhang, Liqian Gao, Zhimin Zhang, Shao Qin Yao

Journal of the American Chemical Society

DOI

2024

Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer

Hong Wang, Huizi Sun, Jie Huang, Zhenhua Zhang, Guodi Cai, Chaofan Wang, Kai Xiao, Xiao‐Feng Xiong, Jian Zhang, Peiqing Liu, Xiaoyun Lu, Weineng Feng, Junjian Wang

EMBO Molecular Medicine

DOI

2024

Dynamics Playing a Key Role in the Covalent Binding of Inhibitors to Focal Adhesion Kinase

Yiling Liu, Jundong Tan, Shiliang Hu, Muzammal Hussain, Chang Qiao, Yaoquan Tu, Xiaoyun Lu, Yang Zhou

Journal of Chemical Information and Modeling

DOI

2024

Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations

Xuan Zheng, Zhiwen Chen, Ming Guo, Hong Liang, Xiaojuan Song, Yiling Liu, Zhenling Liao, Yan Zhang, Jing Guo, Yang Zhou, Zhimin Zhang, Zhimin Zhang, Zhengchao Tu, Zhang Ye, Yongheng Chen, Zhang Zhang, Zhang Zhang, Xiaoyun Lu

ACS Pharmacology & Translational Science

DOI

2023

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo

Mengzhen Lai, Zhang Tao, Hao Chen, Pei-ran Song, Lin-jiang Tong, Jiaying Chen, Yingqiang Liu, Yi Ning, Fang Feng, Yan Li, Haotian Tang, Yi Chen, Yan-feng Fang, Xiaoyun Lu, M. Geng, Ke Ding, K. Yu, Jian Ding, Hua Xie

Journal of Cancer

DOI

2023

Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry.

Guang-Hui Tang, Wei Wang, Xuan Wang, Ke Ding, S. C. Ngan, Jiaojiao Chen, S. Sze, Li-Qian Gao, Pei-Yan Yuan, Xiaoyun Lu, Shao Q. Yao

European journal of medicinal chemistry

DOI

2023

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib

Shuang Xiang, Xiaoyun Lu

Acta Pharmaceutica Sinica B

DOI

2023

Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations

Zuqin Wang, Jie Wang, Yongjin Wang, Shuang Xiang, Hengliang Zhou, Shukai Song, Xiaojuan Song, Zhengchao Tu, Yang Zhou, Ke Ding, Zhimin Zhang, Zhang Zhang, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2023

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations

Hao Chen, Shiliang Hu, Adam Vorn Patterson, Jeff Bruce Smaill, Ke Ding, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2023

Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy

Chaofan Wang, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2023

Rational Design of Covalent Kinase Inhibitors by an Integrated Computational Workflow (Kin-Cov)

Yang Zhou, Hang Yu, Anna Constance Vind, Lulu Kong, Yiling Liu, Xiaojuan Song, Zhengchao Tu, Cai‐Hong Yun, Jeff Bruce Smaill, Qingwen Zhang, Ke Ding, Simon Bekker‐Jensen, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2023

Design, Synthesis, and Evaluation of (R)-8-((Tetrahydrofuran-2-yl)methyl)pyrido[2,3-d]pyrimidin-7-ones as Novel Selective ACK1 Inhibitors to Combat Acquired Resistance to the Third-Generation EGFR Inhibitor

Qian Li, Tao Zhang, Peiran Song, Linjiang Tong, Fang Fěng, Jing Guo, Yang Zhou, Hua Xie, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2023

Advances in protein kinase drug discovery through targeting gatekeeper mutations

Jing Guo, Yang Zhou, Xiaoyun Lu

Expert Opinion on Drug Discovery

DOI

2022

水分子在药物设计中的作用

周洋，陆小云

《药学进展》

2022

Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.

Zu-Qin Wang, Jie Wang, Yong-Jin Wang, Shuang-Lin Xiang, Xiao-Juan Song, Zhengchao Tu, Yang Zhou, Zhi-Min Zhang, Zhang Zhang, Ke Ding, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2022

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.

Min-Kun Shao, Xiaojuan Chen, Fang Yang, Xiao-Juan Song, Yang Zhou, Q. Lin, Ying Fu, R. Ortega, Xiao-Jing Lin, Zhengchao Tu, A. Patterson, J. Smaill, Yongheng Chen, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2022

Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.

Hao Chen, Mengzhen Lai, Zhang Tao, Yuqing Chen, Lin-jiang Tong, Su-Jie Zhu, Yang Zhou, Xiao-Mei Ren, Jian Ding, Hua Xie, Xiaoyun Lu, Ke Ding

Journal of Medicinal Chemistry

DOI

2022

Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants.

Shanshan Li, Zhang Tao, Su-Jie Zhu, Chong Lei, Mengzhen Lai, Lijie Peng, Lin-jiang Tong, Zilu Pang, Xiaoyun Lu, Jian Ding, Xiao-Mei Ren, Cai-Hong Yun, Hua Xie, Ke Ding

ACS Medicinal Chemistry Letters

DOI

2022

Application of deep generative model for design of Pyrrolo[2,3-d] pyrimidine derivatives as new selective TANK binding kinase 1 (TBK1) inhibitors

Shukai Song, Haotian Tang, Ting Ran, Fang Fěng, Linjiang Tong, Hongming Chen, Hua Xie, Xiaoyun Lu

European Journal of Medicinal Chemistry

DOI

2022

JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo

Jie Wang, Yang Zhou, Xia Tang, Xiuwen Yu, Yong-Jin Wang, Shingpan Chan, Xiao-Juan Song, Zhengchao Tu, Zhi-Min Zhang, Xiaoyun Lu, Zhang Zhang, Ke Ding

Molecules

DOI

2022

Targeted inhibition of ZAK ameliorates renal interstitial fibrosis.

Shuang-Shuang Shu, Han Liu, Jian-Zhang Yang, Haie Tang, Hao Li, Zhuo-Liang Liu, Miao-Miao Zhou, F. Zhu, Zheng Hu, Ke Ding, Xiaoyun Lu, Jing Nie

Translational Research: The Journal of Laboratory and Clinical Medicine

DOI

2022

Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy

Yang Zhou, Min Shao, Weiwei Wang, Chen‐Yi Cheung, Yu Wu, Hang Yu, Xianglong Hu, Gregory Murray Cook, Hongri Gong, Xiaoyun Lu

European Journal of Medicinal Chemistry

DOI

2022

Targeting Gatekeeper Mutations for Kinase Drug Discovery

Yang Zhou, Shuang Xiang, Fang Yang, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2022

Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy

Shuang Xiang, Jie Wang, Huisi Huang, Zuqin Wang, Xiaojuan Song, Yang Zhou, Feng Jin, Xun Jun He, Zhimin Zhang, Zhengchao Tu, Ke Ding, Zhang Zhang, Xiaoyun Lu

European Journal of Medicinal Chemistry

DOI

2022

Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment

Chaofan Wang, Jie Li, Lingzhi Qu, Xia Tang, Xiaojuan Song, Fang Yang, Xiaojuan Chen, Qianmeng Lin, Weibin Lin, Yang Zhou, Zhengchao Tu, Yongheng Chen, Zhang Zhang, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2022

Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors

Fang Yang, Xiaojuan Chen, Xiaojuan Song, Raquel Ortega, Xiaojing Lin, Wuqing Deng, Jing Guo, Zhengchao Tu, Adam Vorn Patterson, Jeff Bruce Smaill, Yongheng Chen, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2022

Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders

Jibu Lu, Yong-Jun Huang, Jing Huang, Rui Rochelle He, Minhao Huang, Xiaoyun Lu, Yong Xu, Fengtao Zhou, Zhang Zhang, Ke Ding

Journal of Medicinal Chemistry

DOI

2022

Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC

Fang Yang, Yalei Wen, Chaofan Wang, Yuee Zhou, Yang Zhou, Zhimin Zhang, Tongzheng Liu, Xiaoyun Lu

European Journal of Medicinal Chemistry

DOI

2021

激酶小分子抑制剂研究进展

龙春庭，邵敏，陆小云

《药学学报》

DOI

2021

Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents.

Y. Wu, Chen-Yi Cheung, Yang Zhou, Zhen Wang, Zhengchao Tu, G. Cook, Xiaoyun Lu

Bioorganic & Medicinal Chemistry

DOI

2021

TANK-binding kinase 1 (TBK1): an emerging therapeutic target for drug discovery.

Shuang-Lin Xiang, Shukai Song, Haotian Tang, J. Smaill, Aiqun Wang, Hua Xie, Xiaoyun Lu

Drug Discovery Today

DOI

2021

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.

Xiaoyun Lu, J. Smaill, A. Patterson, Ke Ding

Journal of Medicinal Chemistry

DOI

2021

Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

Wuqing Deng, Xiaojuan Chen, Kaili Jiang, Xiao-Juan Song, Minhao Huang, Zhengchao Tu, Zhang Zhang, Xiao-Jing Lin, R. Ortega, A. Patterson, J. Smaill, Ke Ding, Su-Ming Chen, Yongheng Chen, Xiaoyun Lu

ACS Medicinal Chemistry Letters

DOI

2021

Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies.

Jing Guo, Shuang-Lin Xiang, Jie Wang, Yang Zhou, Zu-Qin Wang, Zhang Zhang, Ke Ding, Xiaoyun Lu

European journal of medicinal chemistry

DOI

2021

LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo

Yingqiang Liu, Mengzhen Lai, Shan Li, Yanan Wang, Fang Feng, Tao Zhang, Lin-jiang Tong, Mengge Zhang, Hao Chen, Yi Chen, Pei-ran Song, Yan Li, Gang Bai, Yi Ning, Haotian Tang, Yan-feng Fang, Xiaoyun Lu, M. Geng, Ke Ding, Kai Yu, Hua Xie, Jian Ding

Cancer Science

DOI

2021

Deep learning-driven scaffold hopping in the discovery of Akt kinase inhibitors.

Zu-Qin Wang, T. Ran, Fang Xu, Chang Wen, Shukai Song, Yang Zhou, Hong-Ming Chen, Xiaoyun Lu

Chemical Communications

DOI

2020

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation

Liang W. Jiang, Yu-Ting Wang, Qian Li, Zhengchao Tu, Si-Hua Zhu, Sanfang Tu, Zhang Zhang, Ke Ding, Xiaoyun Lu

Acta Pharmaceutica Sinica B

DOI

2020

基于片段的药物设计研究进展

郭靖，陆小云

《药学进展》

2020

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.

Hao Chen, J. Smaill, Tongzheng Liu, Ke Ding, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2020

Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.

Xiaoyun Lu, J. Smaill, Ke Ding

Journal of Medicinal Chemistry

DOI

2020

Design and Optimization of 3'-(Imidazo[1,2-a]pyrazin-3-yl)-[1,1'-biphenyl]-3-carboxamides as Selective DDR1 Inhibitors.

Cheng Mo, Zhang Zhang, Yu-Peng Li, Minhao Huang, Jian Zou, Jin-Feng Luo, Zhengchao Tu, Yong Xu, Xiao-Mei Ren, Ke Ding, Xiaoyun Lu

ACS Medicinal Chemistry Letters

DOI

2020

MmpL3 inhibitors as antituberculosis drugs.

Min-Kun Shao, Matthew B. McNeil, G. Cook, Xiaoyun Lu

European journal of medicinal chemistry

DOI

2020

CHAPTER 8. Chemical Probes for Kinases

Xiaoyun Lu, J. Smaill, Ke Ding

DOI

2020

Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.

Minhao Huang, Yong-Jun Huang, Jing Guo, Lei Yu, Yu Chang, Xiaolu Wang, Jin-Feng Luo, Yanhui Huang, Zhengchao Tu, Xiaoyun Lu, Yong Xu, Zhi-Min Zhang, Zhang Zhang, Ke Ding

European journal of medicinal chemistry

DOI

2020

The synthesis and biological evaluation of sanguinarine derivatives as anti-non-small cell lung cancer agents.

Liang W. Jiang, Xiaolu Wang, Yu-Ting Wang, Fang Xu, Zhang Zhang, Ke Ding, Xiaoyun Lu

RSC Medicinal Chemistry

DOI

2020

2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant

Xianglong Hu, Qiuju Xun, Tao Zhang, Su-Jie Zhu, Qian Li, Lin-jiang Tong, Mengzhen Lai, Tao Huang, Cai-Hong Yun, Hua Xie, Ke Ding, Xiaoyun Lu

DOI

2020

New techniques and strategies in drug discovery

Jintong Du, Jing Guo, Dong-Wei Kang, Zhi-Hong Li, Guan Wang, Jian-Bing Wu, Zhen Zhang, H. Fang, Xu-Ben Hou, Zhangjian Huang, Guo-Bo Li, Xiaoyun Lu, Xin-Yong Liu, L. Ouyang, Li Rao, Peng Zhan, Xiao-Jin Zhang, Yihua Zhang

Chinese Chemical Letters

DOI

2020

New antituberculosis drugs targeting the respiratory chain

Qian Li, Xiaoyun Lu

DOI

2020

Design and synthesis of selective degraders of EGFRL858R/T790M mutant.

Xin Zhang, Fang Xu, Lin-jiang Tong, Tao Zhang, Hua Xie, Xiaoyun Lu, Xiao-Mei Ren, Ke Ding

European journal of medicinal chemistry

DOI

2020

Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-alpha Motif Kinase (ZAK) Inhibitors.

J. Yang, Shibu, L. Kong, Jin-Feng Luo, F. BadrealamKhan, Y. Huang, Zhengchao Tu, Cai-Hong Yun, Chih-Yang Huang, Ke Ding, Xiaoyun Lu

DOI

2019

Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors.

Jian-Zhang Yang, M. Shibu, L. Kong, Jin-Feng Luo, F. BadrealamKhan, Yanhui Huang, Zhengchao Tu, Cai-Hong Yun, Chih-Yang Huang, Ke Ding, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2019

Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S).

Jiayi Shen, Tao Zhang, Shu-Jie Zhu, Min Sun, Lin-jiang Tong, Mengzhen Lai, Rong-Kai Zhang, Wei Xu, Ruibo Wu, Jian Ding, Cai-Hong Yun, Hua Xie, Xiaoyun Lu, Ke Ding

Journal of Medicinal Chemistry

DOI

2019

2-Amino-2,3-dihydro-1H-indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy

Dongsheng Zhu, Huocong Huang, D. Pinkas, Jin-Feng Luo, Debolina Ganguly, A. E. Fox, Emily N. Arner, Qiu-Ping Xiang, Zhengchao Tu, A. Bullock, R. Brekken, Ke Ding, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2019

Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.

Xiao-Jing Lin, Y. Yosaatmadja, M. Kalyukina, M. Middleditch, Zhen Zhang, Xiaoyun Lu, Ke Ding, A. Patterson, J. Smaill, C. Squire

ACS Medicinal Chemistry Letters

DOI

2019

New Promise and Opportunities for Allosteric Kinase Inhibitors.

Xiaoyun Lu, J. Smaill, Ke Ding

Angewandte Chemie

DOI

2019

Quinolone antibiotic derivatives as new selective Axl kinase inhibitors.

Li Tan, Zhang Zhang, Dong-Lin Gao, Shingpan Chan, Jin-Feng Luo, Zhengchao Tu, Zhi-Min Zhang, Ke Ding, Xiao-Mei Ren, Xiaoyun Lu

European journal of medicinal chemistry

DOI

2019

Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents.

Xianglong Hu, B. Wan, Yang Liu, Jiayi Shen, S. Franzblau, Tianyu Zhang, Ke Ding, Xiaoyun Lu

ACS Medicinal Chemistry Letters

DOI

2019

Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.

Shengyang Cui, Yong-Jin Wang, Yu-Ting Wang, Xia Tang, Xiao-Mei Ren, Lei Zhang, Yong Xu, Zhang Zhang, Zhi-Min Zhang, Xiaoyun Lu, Ke Ding

European journal of medicinal chemistry

DOI

2019

Small-Molecule CSF1R Inhibitors as Anticancer Agents.

Qiuju Xun, Zhen Wang, Xianglong Hu, Ke Ding, Xiaoyun Lu

Current Medicinal Chemistry

DOI

2019

Assessment of Clofazimine and TB47 Combination Activity against Mycobacterium abscessus Using a Bioluminescent Approach

Yang Liu, Yaoju Tan, Md. Mahmudul Islam, Yuanyuan Cao, Xiaoyun Lu, Sheng Zeng, H. M. Adnan Hameed, Peipei Zhou, Xingshan Cai, Shuai Wang, Julius Mugweru, Guoliang Zhang, Huancai Yin, Jianxiong Liu, Eric L. Nuermberger, Tianyu Zhang

Antimicrobial Agents and Chemotherapy

DOI

2019

Allosterische Kinaseinhibitoren – Erwartungen und Chancen

Xiaoyun Lu, Jeff Bruce Smaill, Ke Ding

Angewandte Chemie

DOI

2018

Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2

Zhen Wang, Ya-Li Zhang, D. Pinkas, A. E. Fox, Jin-Feng Luo, Huocong Huang, Shengyang Cui, Qiu-Ping Xiang, Ting-Ting Xu, Qiuju Xun, Dongsheng Zhu, Zhengchao Tu, Xiao-Mei Ren, R. Brekken, A. Bullock, G. Liang, Ke Ding, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2018

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.

Xiaoyun Lu, Hao Chen, A. Patterson, J. Smaill, Ke Ding

Journal of Medicinal Chemistry

DOI

2018

Design, Synthesis, and Structure-Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5- d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors.

Qiuju Xun, Zhang Zhang, Jin-Feng Luo, Lin-jiang Tong, Minhao Huang, Zhen Wang, Jian Zou, Yingqiang Liu, Yong Xu, Hua Xie, Zhengchao Tu, Xiaoyun Lu, Ke Ding

Journal of Medicinal Chemistry

DOI

2018

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

Xiaoyun Lu, Lei Yu, Zhang Zhang, Xiao-Mei Ren, J. Smaill, Ke Ding

Medicinal research reviews (Print)

DOI

2018

Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R

Yingqiang Liu, Yanan Wang, Xiaoyun Lu, Lin-jiang Tong, Yan Li, Tao Zhang, Qiuju Xun, Fang Feng, Yuzhe Chen, Yi Su, Yan-yan Shen, Yi Chen, M. Geng, Ke Ding, Yan-Li Li, Hua Xie, Jian Ding

Acta Pharmacologica Sinica

DOI

2018

YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M‐mutant resistance in vitro and in vivo

Zhang Zhang, Jian Zou, Lei Yu, Jin-Feng Luo, Yan Li, Zhengchao Tu, Xiao-Mei Ren, Hongcheng Wei, Li-Yan Song, Xiaoyun Lu, Ke Ding

Cancer Medicine

DOI

2018

GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models

Jian Zou, Zhang Zhang, Fang Xu, Shengyang Cui, Chunli Qi, Jin-Feng Luo, Zhen Wang, Xiaoyun Lu, Zhengchao Tu, Xiao-Mei Ren, Li-Yan Song, Ke Ding

Journal of drug targeting (Print)

DOI

2018

Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy.

Xiaoyun Lu, Tao Zhang, Su-Jie Zhu, Qiuju Xun, Ling-jiang Tong, Xianglong Hu, Yan Li, Shingpan Chan, Yi Su, Yiming Sun, Yi Chen, Jian Ding, Cai-Hong Yun, Hua Xie, Ke Ding

ACS Medicinal Chemistry Letters

DOI

2018

Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis.

Xiaoyun Lu, Zoe C Williams, Kiel Hards, Jian-Feng Tang, Chen-Yi Cheung, H. Aung, Bang-Xing Wang, Zhi-Yong Liu, Xianglong Hu, A. Lenaerts, Lisa K. Woolhiser, Courtney Hastings, Xiantao Zhang, Zhe Wang, K. Rhee, Ke Ding, Tianyu Zhang, G. Cook

ACS Infectious Diseases

DOI

2017

Structure Based Design of N-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides as Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors.

Yu Chang, Xiaoyun Lu, M. Shibu, Yi-Bo Dai, Jin-Feng Luo, Yan Zhang, Ying-Jun Li, Peng Zhao, Zhang Zhang, Yong Xu, Zhengchao Tu, Qing-Wen Zhang, Cai-Hong Yun, Chih-Yang Huang, Ke Ding

Journal of Medicinal Chemistry

DOI

2017

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.

Cheng Mo, Zhang Zhang, C. Guise, Xue-Qiang Li, Jin-Feng Luo, Zhengchao Tu, Yong Xu, A. Patterson, J. Smaill, Xiao-Mei Ren, Xiaoyun Lu, Ke Ding

ACS Medicinal Chemistry Letters

DOI

2017

Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance

Xiaoyun Lu, Zhang Zhang, Xiao-Mei Ren, De-Ping Wang, Ke Ding

Journal of Enzyme Inhibition and Medicinal Chemistry

DOI

2017

Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors.

Zhen Wang, Ya-Li Zhang, S. G. Bartual, Jin-Feng Luo, Ting-Ting Xu, Wen-Ting Du, Qiuju Xun, Zhengchao Tu, R. Brekken, Xiao-Mei Ren, A. Bullock, G. Liang, Xiaoyun Lu, Ke Ding

ACS Medicinal Chemistry Letters

DOI

2017

Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant Mycobacterium tuberculosis.

Xiaoyun Lu, Xianglong Hu, Zhi-Yong Liu, Tianyu Zhang, Rui-Bing Wang, B. Wan, S. Franzblau, Q. You

MedChemComm

DOI

2017

A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.

Lei Yu, Minhao Huang, Tianfeng Xu, Lin-jiang Tong, Xiao-E Yan, Zhang Zhang, Yong Xu, Cai-Hong Yun, Hua Xie, Ke Ding, Xiaoyun Lu

European journal of medicinal chemistry

DOI

2017

Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity.

Xiaoyun Lu, Jian-Feng Tang, Shengyang Cui, B. Wan, Scott G Franzblauc, Tianyu Zhang, Xiantao Zhang, Ke Ding

European journal of medicinal chemistry

DOI

2017

2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.

Xue-Qiang Li, C. Guise, Rana Taghipouran, Y. Yosaatmadja, A. Ashoorzadeh, W.-K. Paik, C. Squire, Shuang Jiang, Jin-Feng Luo, Yong Xu, Zhengchao Tu, Xiaoyun Lu, Xiao-Mei Ren, A. Patterson, J. Smaill, Ke Ding

European journal of medicinal chemistry

DOI

2016

Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.

Xiaokai Li, Jiayi Shen, Li Tan, Zhang Zhang, Dong-Lin Gao, Jin-Feng Luo, Huimin Cheng, Xiao-Ping Zhou, Jie Ma, Ke Ding, Xiaoyun Lu

Bioorganic & Medicinal Chemistry Letters

DOI

2016

Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis.

Xiaoyun Lu, Jian-Feng Tang, Zhi-Yong Liu, Minke Li, Tianyu Zhang, Xiantao Zhang, Ke Ding

Bioorganic & Medicinal Chemistry Letters

DOI

2016

Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors

Zhen Wang, H. Bian, S. G. Bartual, Wen-Ting Du, Jin-Feng Luo, Hu Zhao, Sha-Sha Zhang, Cheng Mo, Yang Zhou, Yong Xu, Zhengchao Tu, Xiao-Mei Ren, Xiaoyun Lu, R. Brekken, Li-Bo Yao, Alex N. Bullock, Jin Su, Ke Ding

Journal of Medicinal Chemistry

DOI

2016

選択的ジスコイジンドメイン受容体1(DDR1)阻害剤としてのテトラヒドロイソキノリン‐7‐カルボキシアミドの構造基盤デザイン

Zhen Wang, H. Bian, G. Sergio, Wen-Ting Du, Jin-Feng Luo, Hu Zhao, Sha-Sha Zhang, Cheng Mo, Yang Zhou, Yong Xu, Zhengchao Tu, Xiao-Mei Ren, Xiaoyun Lu, A. Rolf, Li-Bo Yao, N. Alex, Jin Su, Ke Ding

2016

GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo.

Zhang Zhang, Xiao-Mei Ren, Xiaoyun Lu, De-Ping Wang, Xianjing Hu, Yi Zheng, Li-Yan Song, Hongwen Pang, Rong-Min Yu, Ke Ding

Cancer Letters

DOI

2016

Leucine-zipper and Sterile-α Motif Kinase (ZAK): A Potential Target for Drug Discovery.

Yu Chang, Qing-Wen Zhang, Zhengqiu Li, Ke Ding, Xiaoyun Lu

Current Medicinal Chemistry

DOI

2016

GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways

W. Ye, Zhiwu Jiang, Xiaoyun Lu, Xiao-Mei Ren, Manman Deng, Shouheng Lin, Yi-Ren Xiao, Si-Miao Lin, Suna Wang, Baiheng Li, Yi Zheng, P. Lai, J. Weng, Dong-Hai Wu, Yuguo Ma, Xu-Dong Chen, Z. Wen, Yao-Yu Chen, Xiao-Min Feng, Yangqiu Li, Pentao Liu, Xin Du, D. Pei, Yao Yao, Bing Xu, K. Ding, Peng Li

OncoTarget

DOI

2016

3‐aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors

Jiayi Shen, Xiaokai Li, Zhang Zhang, Jing-Feng Luo, Huo-You Long, Zhengchao Tu, Xiao-Ping Zhou, Ke Ding, Xiaoyun Lu

Chemical Biology and Drug Design

DOI

2016

Small Molecule Inhibitors of Discoidin Domain Receptors (DDRs)

Xiaoyun Lu, Ke Ding

DOI

2015

抗白血病新药普纳替尼的合成

姜霜，冯玉冰，丁克，陆小云

《中国药物化学杂志》

2015

Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.

Xiaoyun Lu, Zhang Zhang, Xiao-Mei Ren, Xiao-Fen Pan, De-Ping Wang, Xiao-Xi Zhuang, Jing-Feng Luo, Rong-Min Yu, Ke Ding

Bioorganic & Medicinal Chemistry Letters

DOI

2015

Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.

Yu-Peng Li, Xiaoyun Lu, Xiao-Mei Ren, Ke Ding

Journal of Medicinal Chemistry

DOI

2015

2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).

Shingpan Chan, Kun Han, Rong Qu, Lin-jiang Tong, Ying-Jun Li, Zhang Zhang, Huimin Cheng, Xiaoyun Lu, A. Patterson, J. Smaill, Xiao-Mei Ren, Jian Ding, Hua Xie, Ke Ding

Bioorganic & Medicinal Chemistry Letters

DOI

2015

Bacterial β-ketoacyl-acyl carrier protein synthase III (FabH) as a target for novel antibacterial agents design.

Xiaoyun Lu, Ji-Ping Tang, Z. Zhang, Ke Ding

Current Medicinal Chemistry

DOI

2015

Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents.

Jian-Feng Tang, Bang-Xing Wang, Tian Wu, J. Wan, Zhengchao Tu, Moses Njire, B. Wan, Scott G Franzblauc, Tianyu Zhang, Xiaoyun Lu, Ke Ding

ACS Medicinal Chemistry Letters

DOI

2015

Substituted quinolone derivative or pharmaceutically acceptable salts or stereoisomers thereof and pharmaceutical composition and application thereof

Ke Ding, M. Geng, Li Tan, Jian Ding, Zhang Zhang, Jing Ai, Xiao-Mei Ren, Dong-Lin Gao, Zhengchao Tu, Xiaoyun Lu, Dong-Mei Zhang

2015

Small-molecule BET inhibitors in clinical and preclinical development and their therapeutic potential.

Lei Yu, Zhen Wang, Zhang Zhang, Xiao-Mei Ren, Xiaoyun Lu, Ke Ding

Current Topics in Medicinal Chemistry

DOI

2015

C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant

Tianfeng Xu, Ting Peng, Xiao-Mei Ren, Lian-Wen Zhang, Lei-Ping Yu, Jin-Feng Luo, Zhang Zhang, Zhengchao Tu, Lin-jiang Tong, Zhaoru Huang, Xiaoyun Lu, M. Geng, Hua Xie, Jian Ding, Ke Ding

DOI

2014

Novel anaplastic lymphoma kinase inhibitors targeting clinically acquired resistance.

Xiaoyun Lu, Ke Ding

Journal of Medicinal Chemistry

DOI

2014

Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.

Huimin Cheng, Yu Chang, Lian-Wen Zhang, Jin-Feng Luo, Zhengchao Tu, Xiaoyun Lu, Qing-Wen Zhang, Ji-Bu Lu, Xiao-Mei Ren, Ke Ding

Journal of Medicinal Chemistry

DOI

2014

Design, synthesis and antitubercular evaluation of new 2-amino-5-(4-(benzyloxy)benzyl)thiophene-3-carboxylic acid derivatives. Part 3

Xiaoyun Lu, Jian-Feng Tang, Q. You, B. Wan, S. Franzblau

DOI

2014

一种 ddr2 小分子抑制剂抗肺纤维化应用

Jin Su, Ke Ding, Hu Zhao, Li-B. Yao, Xin Bo, Xiao-Mei Ren, Xiaoyun Lu, Jiang-Tian Yu, De-Ping Wang

2013

Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.

Xiao-Mei Ren, Xiao-Fen Pan, Zhang Zhang, De-Ping Wang, Xiaoyun Lu, Yu-Peng Li, Donghai Wen, Huo-You Long, Jin-Feng Luo, Yu-Bing Feng, Xiao-Xi Zhuang, Fengxiang Zhang, Jian-Qi Liu, Fang Leng, Xingfen Lang, Yang Bai, M. She, Zhengchao Tu, Jing-Xuan Pan, Ke Ding

Journal of Medicinal Chemistry

DOI

2013

Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.

Mingshan Gao, Lei Duan, Jin-Feng Luo, Lian-Wen Zhang, Xiaoyun Lu, Yan Zhang, Zhang Zhang, Zhengchao Tu, Yong Xu, Xiao-Mei Ren, Ke Ding

Journal of Medicinal Chemistry

DOI

2013

Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.

Shili Xu, Tianfeng Xu, Lian-Wen Zhang, Zhang Zhang, Jin-Feng Luo, Yingxue Liu, Xiaoyun Lu, Zhengchao Tu, Xiao-Mei Ren, Ke Ding

Journal of Medicinal Chemistry

DOI

2013

Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants.

Tianfeng Xu, Lian-Wen Zhang, Shili Xu, Chao-Yie Yang, Jin-Feng Luo, Fang Ding, Xiaoyun Lu, Yingxue Liu, Zhengchao Tu, Shi-Liang Li, D. Pei, Q. Cai, Honglin Li, Xiao-Mei Ren, Shaomeng Wang, Ke Ding

Angewandte Chemie

DOI

2013

Pyrimido heterocyclic compounds and pharmaceutical compositions and uses

Ke Ding, Shili Xu, Tianfeng Xu, Lian-Wen Zhang, Fang Ding, Zhengchao Tu, Xiaoyun Lu, Jian Ding, M. Geng

2013

7-oxo-pyridopyrimidine derivatives, pharmaceutical compositions and uses thereof

Ke Ding, Tianfeng Xu, Fang Ding, Lian-Wen Zhang, Xiaoyun Lu, Wei-Hua Li, Jian Ding, M. Geng

2013

Compound used as estrogen-related receptor regulator and application of compound

Ke Ding, Shili Xu, Xiao-Xi Zhuang, Xiao-Fen Pan, Zhang Zhang, Lei Duan, Xiaoyun Lu

2012

Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.

Yu-Peng Li, M. Shen, Zhang Zhang, Jin-Feng Luo, Xiao-Fen Pan, Xiaoyun Lu, Huo-You Long, Donghai Wen, Fengxiang Zhang, Fang Leng, Ying-Jun Li, Zhengchao Tu, Xiao-Mei Ren, Ke Ding

Journal of Medicinal Chemistry

DOI

2012

Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.

Shao-Hua Chang, Lian-Wen Zhang, Shili Xu, Jin-Feng Luo, Xiaoyun Lu, Zhang Zhang, Tianfeng Xu, Yingxue Liu, Zhengchao Tu, Yong Xu, Xiao-Mei Ren, M. Geng, Jian Ding, D. Pei, Ke Ding

Journal of Medicinal Chemistry

DOI

2012

New thiazole carboxamides as potent inhibitors of Akt kinases.

Shao-Hua Chang, Zhang Zhang, Xiao-Xi Zhuang, Jin-Feng Luo, Xian-Wen Cao, Honglin Li, Zhengchao Tu, Xiaoyun Lu, Xiao-Mei Ren, Ke Ding

Bioorganic & Medicinal Chemistry Letters

DOI

2012

Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2.

Xiaoyun Lu, Xiao-Bo Liu, B. Wan, S. Franzblau, Li-Li Chen, Chang-Lin Zhou, Q. You

European journal of medicinal chemistry

DOI

2012

Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790→ methionine790 mutant

Shili Xu, Lian-Wen Zhang, Shao-Hua Chang, Jin-Feng Luo, Xiaoyun Lu, Zhengchao Tu, Yingxue Liu, Zhang Zhang, Yong Xu, Xiao-Mei Ren, Ke Ding

DOI

2012

Pharmacophore and Molecular Docking Guided 3D-QSAR Study of Bacterial Enoyl-ACP Reductase (FabI) Inhibitors

Xiaoyun Lu, Man Lv, Kun Huang, Ke Ding, Q. You

International Journal of Molecular Sciences

DOI

2012

Recent advance in the design of small molecular modulators of estrogen-related receptors.

Xiaoyun Lu, Lijie Peng, Man Lv, Ke Ding

Current pharmaceutical design

DOI

2012

Alkynyl pyrazolopyridine compounds and pharmaceutical compositions benzene and applications

Ke Ding, Yu-Bing Feng, Xiaoyun Lu, Xiao-Fen Pan, Zhang Zhang, Huo-You Long, Xiao-Mei Ren, Wei-Hua Li

2012

Pyrimido diazepine-based compounds and pharmaceutical compositions and uses

Ke Ding, Shili Xu, Shao-Hua Chang, Lian-Wen Zhang, Zhengchao Tu, Yong Xu, Xiaoyun Lu

2011

Hybrid compounds as new Bcr/Abl inhibitors.

De-Ping Wang, Zhang Zhang, Xiaoyun Lu, Yu-Bing Feng, K. Luo, J. Gan, Liu Yingxue, J. Wan, Xiang Li, Fengxiang Zhang, Zhengchao Tu, Q. Cai, Xiao-Mei Ren, Ke Ding

Bioorganic & Medicinal Chemistry Letters

DOI

2011

Design, synthesis and anti-tubercular evaluation of new 2-acylated and 2-alkylated amino-5-(4-(benzyloxy)phenyl)thiophene-3-carboxylic acid derivatives. Part 1.

Xiaoyun Lu, B. Wan, S. Franzblau, Q. You

European journal of medicinal chemistry

DOI

2011

Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation.

Xiaoyun Lu, Q. Cai, Ke Ding

Current Medicinal Chemistry

DOI

2011

Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 – 2010)

Xiaoyun Lu, Kun Huang, Q. You

Expert Opinion on Therapeutic Patents

DOI

2010

3D-QSAR, molecular docking studies, and binding mode prediction of thiolactomycin analogs as mtFabH inhibitors

Xiaoyun Lu, Ya-Dong Chen, Q. You

Journal of Enzyme Inhibition and Medicinal Chemistry

DOI

2010

Molecular-docking-guided 3D-QSAR studies of substituted isoquinoline-1,3-(2H,4H)-diones as cyclin-dependent kinase 4 (CDK4) inhibitors

Xiaoyun Lu, Ya-Dong Chen, Nina Sun, Yong-Jun Jiang, Q. You

Journal of Molecular Modeling

DOI

2010

3D‐QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore‐based alignment

Xiaoyun Lu, Ya-Dong Chen, Q. You

Chemical Biology and Drug Design

DOI

2010

Recent advances on platensimycin: a potential antimicrobial agent.

Xiaoyun Lu, Q. You

Current Medicinal Chemistry

DOI

2009

2-(6-氯胡椒基)-3[4-(2,6-二氯苄氧基)苯基]丙酸的合成

陆小云，尤启冬

《中国医药工业杂志》

2009

Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.

Xiaoyun Lu, Ya-Dong Chen, Yong-Jun Jiang, Q. You

European journal of medicinal chemistry

DOI

2009

Pharmacophore Guided 3D‐QSAR CoMFA Analysis of Amino Substituted Nitrogen Heterocycle Ureas as KDR Inhibitors

Xiaoyun Lu, Ya-Dong Chen, Q. You

DOI

2008

As estrogen-related receptor modulator compounds and uses thereof

Ke Ding, Shili Xu, Xiao-Xi Zhuang, Xiao-Fen Pan, Zhang Zhang, Lei Duan, Xiaoyun Lu

2008

Recent progress of SRC family kinase inhibitors as anticancer agents.

Xin Cao, Q. You, Zhi-yu Li, Xiao-Jian Wang, Xiaoyun Lu, Xiao-Rong Liu, Dan Xu, Bao Liu

Mini-Reviews in Medical Chemistry

DOI

精选作品

期刊论文

2025年美国FDA批准的小分子激酶抑制剂综述

Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance.

Discovery of Arginine-Reactive Covalent Kinase Inhibitors Overcoming Clinical Drug Resistance

Discovery and Synthesis of Selective Casein Kinase 1δ Degraders for Suppressing Oncogenic NRAS-Mutant Melanoma

p38β-mediated BiP phosphorylation drives stemness and chemoresistance by suppressing UPR activation in hepatocellular carcinoma

Structure-Based Design of 4-(1-Methyl-1 H -indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors

Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance

Covalent Recruitment of E3 Ligases: A New Path for Rational Design of Protein Degraders

Design, Synthesis, and Antimicrobial Activity of Novel Cyt- bd Inhibitors Targeting Energy Compensation in Mycobacterium tuberculosis

Dual‐Site Covalent Targeting Enables BD2‐Selective BET Inhibition With Potent Antitumor Activity in Mice

Generative Replica Exchange: A Flow-Based Framework for Accelerating Replica-Exchange Simulations

Large‐Scale Profiling of Kinase Degradation by Using Norbornene‐Based Hydrophobic Tag (HyT) Strategy

List of contributors

Recent advances in HER2-targeted inhibitors for cancer therapy

Discovery of 4-((2S,5R)-2-((difluoromethoxy)methyl)-5-(4-(trifluoromethyl)phenyl)piperidin-1-yl)-N-((R)-1-(4-(ethylsulfonyl)phenyl)-2-hydroxyethyl)benzamide as a potent, orally available RORγt inverse agonist

Structure-Based Virtual Screening Discovers Potent PLK1 Inhibitors with Anticancer Activity

Proteome-Wide Ligand and Target Discovery by Using Covalent Probes and Natural Products

Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1 H -indole-3-yl)-5 H -pyrrolo[2,3- b ]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance

Discovery of TBK1Molecular Glue Degraders as a Potential Strategy for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Designing Macrocyclic Kinase Inhibitors Using Macrocycle Scaffold Hopping with Reinforced Learning (Macro-Hop)

WEE-family kinases in cancer: synthetic lethal interactions and drug discovery

Macrocycle-DB: a comprehensive database for macrocycle-based drug discovery

Cell‐Active, Irreversible Covalent Inhibitors Targeting a Surface‐Exposed Non‐Catalytic Lysine on Aurora a Kinase by Using Squarate Chemistry

Comprehensive Drug-Likeness Prediction Using a Pretrained Transformer Model and Multitask Learning

Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4

Deciphering molecular specificity in MCL-1/BAK interaction and its implications for designing potent MCL-1 inhibitors

Cell‐Active, Arginine‐Targeting Irreversible Covalent Inhibitors for Non‐Kinases and Kinases

2022年FDA批准的激酶调节剂浅析

Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma

Design, Synthesis, and Biological Evaluation of Novel Diaminopyrimidine Macrocycles as Fourth Generation Reversible EGFR Inhibitors That Overcome Clinical Resistance to Osimertinib Mediated by C797S Mutation

Multidisciplinary Training for Fostering Next-Generation Medicinal Chemists

NeoaPred: a deep-learning framework for predicting immunogenic neoantigen based on surface and structural features of peptide–human leukocyte antigen complexes

Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1 -Amplified Breast Cancer

Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies

Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity

A patent review of small molecular inhibitors targeting EGFR exon 20 insertion (Ex20ins) (2019-present)

A Self-Assembled Nano-Molecular Glue (Nano-mGlu) Enables GSH/H 2 O 2 -Triggered Targeted Protein Degradation in Cancer Therapy

Advances in Small-Molecule C-KIT/PDGFRα Inhibitors for the Treatment of Gastrointestinal Stromal Tumors

Small Molecule-Induced Post-Translational Acetylation of Catalytic Lysine of Kinases in Mammalian Cells

Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer

Dynamics Playing a Key Role in the Covalent Binding of Inhibitors to Focal Adhesion Kinase

Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo

Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry.

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib

Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations

Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy

Rational Design of Covalent Kinase Inhibitors by an Integrated Computational Workflow (Kin-Cov)

Design, Synthesis, and Evaluation of (R)-8-((Tetrahydrofuran-2-yl)methyl)pyrido[2,3-d]pyrimidin-7-ones as Novel Selective ACK1 Inhibitors to Combat Acquired Resistance to the Third-Generation EGFR Inhibitor

Advances in protein kinase drug discovery through targeting gatekeeper mutations

水分子在药物设计中的作用

Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.

Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.

Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants.

Application of deep generative model for design of Pyrrolo[2,3-d] pyrimidine derivatives as new selective TANK binding kinase 1 (TBK1) inhibitors

JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo

Targeted inhibition of ZAK ameliorates renal interstitial fibrosis.

Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy

Targeting Gatekeeper Mutations for Kinase Drug Discovery

Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy

Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment

Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors

Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders

Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC

激酶小分子抑制剂研究进展

Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents.

TANK-binding kinase 1 (TBK1): an emerging therapeutic target for drug discovery.

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.

Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies.

LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo

Deep learning-driven scaffold hopping in the discovery of Akt kinase inhibitors.

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation

基于片段的药物设计研究进展

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.